Stockreport

HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience [Seeking Alpha]

Cybin Inc.  (HELP) 
PDF Key 2026 catalysts include Phase 3 data for HLP003 in major depressive disorder and Phase 2 data for HLP004 in generalized anxiety disorder. HELP's cash burn accelera [Read more]